Alnylam Pharmaceuticals(US:ALNY)2024-05-02 15:36Financial Performance - Alnylam's combined net product revenue reached $365 million, a 32% year-over-year growth compared to Q1 2023[10] - The company's total revenue increased by 55% year-over-year, reaching $494 million in Q1 2024[37] - Alnylam is reiterating its full-year 2024 net product revenue guidance of $1400 million to $1500 million, representing a 13% to 21% growth compared to 2023[38] - Non-GAAP operating profit was $2 million, a significant improvement compared to a $110 million loss in Q1 2023[37] - Cash and investments totaled $2371 million as of March 31, 2024[37] Commercial Highlights - AMVUTTRA is a clear market leader in the treatment of hATTR-PN, with over 95% of patients complying with the dosing regimen[14] - U S TTR franchise YoY growth was +35%, driven by demand for AMVUTTRA[13] - OXLUMO YoY growth of +77% driven by strong demand[18] Pipeline Development - Topline results from the HELIOS-B Phase 3 clinical study of Vutrisiran in ATTR amyloidosis patients with cardiomyopathy are expected in late June/early July 2024[21] - Zilebesiran continues to demonstrate the potential to transform the treatment of hypertension[24] - Alnylam plans to file 3 new INDs (Investigational New Drug applications)[40]